Cited 0 times in

Adjunctive administration of parabiotic Lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosis

Authors
 Hagyu Kim  ;  Eun-Jung Song  ;  Eunsol Choi  ;  Kee Woong Kwon  ;  Jong-Hwan Park  ;  Sung Jae Shin 
Citation
 INTERNATIONAL IMMUNOPHARMACOLOGY, Vol.132 : 111937, 2024-05 
Journal Title
INTERNATIONAL IMMUNOPHARMACOLOGY
ISSN
 1567-5769 
Issue Date
2024-05
MeSH
Animals ; Antitubercular Agents / adverse effects ; Antitubercular Agents / therapeutic use ; Chemical and Drug Induced Liver Injury / drug therapy ; Chemical and Drug Induced Liver Injury / etiology ; Chemical and Drug Induced Liver Injury / immunology ; Female ; Humans ; Interleukin-10 / metabolism ; Latilactobacillus sakei* ; Liver / drug effects ; Liver / immunology ; Liver / pathology ; Lung / drug effects ; Lung / immunology ; Lung / microbiology ; Lung / pathology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mycobacterium tuberculosis* / drug effects ; Mycobacterium tuberculosis* / immunology ; Pneumonia / drug therapy ; Pneumonia / immunology ; Probiotics* / administration & dosage ; Probiotics* / therapeutic use ; T-Lymphocytes, Regulatory / drug effects ; T-Lymphocytes, Regulatory / immunology ; Tuberculosis / drug therapy ; Tuberculosis / immunology
Keywords
Alanine aminotransferase ; Antibiotic treatment ; Hepatoxicity ; Lactobacillus sakei CVL-001 ; Tuberculosis
Abstract
Tuberculosis (TB) treatment requires a long therapeutic duration and induces adverse effects such as hepatotoxicity, causing discontinuation of treatment. Reduced adherence to TB medications elevates the risk of recurrence and the development of drug resistance. Additionally, severe cavitary TB with a high burden of Mycobacterium tuberculosis (Mtb) and inflammation-mediated tissue damage may need an extended treatment duration, resulting in a higher tendency of drug-induced toxicity. We previously reported that the administration of Lactobacillus sakei CVL-001 (L. sakei CVL-001) regulates inflammation and improves mucosal barrier function in a murine colitis model. Since accumulating evidence has reported the functional roles of probiotics in drug-induced liver injury and pulmonary inflammation, we employed a parabiotic form of the L. sakei CVL-001 to investigate whether this supplement may provide beneficial effects on the reduction in drug-induced liver damage and pulmonary inflammation during chemotherapy. Intriguingly, L. sakei CVL-001 administration slightly reduced Mtb burden without affecting lung inflammation and weight loss in both Mtb-resistant and -susceptible mice. Moreover, L. sakei CVL-001 decreased T cell-mediated inflammatory responses and increased regulatory T cells along with an elevated antigen-specific IL-10 production, suggesting that this parabiotic may restrain excessive inflammation during antibiotic treatment. Furthermore, the parabiotic intervention significantly reduced levels of alanine aminotransferase, an indicator of hepatotoxicity, and cell death in liver tissues. Collectively, our data suggest that L. sakei CVL-001 administration has the potential to be an adjunctive therapy by reducing pulmonary inflammation and liver damage during anti-TB drug treatment and may benefit adherence to TB medication in lengthy treatment.
Full Text
https://www.sciencedirect.com/science/article/pii/S1567576924004557
DOI
10.1016/j.intimp.2024.111937
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers
Yonsei Authors
Shin, Sung Jae(신성재) ORCID logo https://orcid.org/0000-0003-0854-4582
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/200166
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links